+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Efficacy and safety of intravenous itraconazole followed by oral itraconazole solution in the treatment of invasive pulmonary mycosis



Efficacy and safety of intravenous itraconazole followed by oral itraconazole solution in the treatment of invasive pulmonary mycosis



Chinese Medical Journal 124(20): 3415-3419



Invasive pulmonary mycosis is the most common type of invasive fungal infection. It is often severe and difficult to treat, and is accompanied by high mortality. In this study, we aimed to evaluate the efficacy and safety of intravenous itraconazole followed by oral itraconazole solution in the treatment of invasive pulmonary mycosis and to determine the distribution of different fungi species. This was a multi-center, open-label study which enrolled 71 patients who were diagnosed as invasive pulmonary mycosis between July 2007 and January 2009. All patients received intravenous itraconazole therapy followed by oral itraconazole solution with a total treatment duration of 6 weeks. Intravenous itraconazole was given at a dose of 200 mg bid (intravenous infusion every 12 hours) for the first two days, 200 mg qd for the subsequent 12 days. Sequential oral itraconazole solution was given at a dose of 100 mg bid for 4 weeks. Efficacy and safety were assessed according to clinical as well as microbiological criteria. Seventy one patients participated in this study. Of the 60 patients in the full analysis dataset, the clinical response rate was 61.7% and the mycological eradication rate was 66.7%. The overall response rate was 66.7%. Drug-related adverse events occurred in 18.0% of patients: hypokalemia, liver function impairment and mild gastrointestinal side effects were the most common. One patient suffered from severe adverse event, with limb and facial swelling. This study showed that in patients with invasive pulmonary mycosis, intravenous itraconazole followed by oral itraconazole solution therapy was safe and effective.

(PDF emailed within 1 workday: $29.90)

Accession: 052896315

Download citation: RISBibTeXText

PMID: 22088546


Related references

Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematologica 109(3): 111-118, 2003

Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clinical Infectious Diseases 33(8): E83-E90, 2001

Efficacy, safety, and pharmacokinetics of intravenous followed by oral itraconazole in patients with invasive pulmonary aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 575, 1999

Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrobial Agents and ChemoTherapy 41(12): 2714-2718, 1998

Correlation of in vitro activity and in vivo efficacy of itraconazole intravenous and oral solubilized formulations by testing Candida strains with various itraconazole susceptibilities in a murine invasive infection. Journal of Antimicrobial ChemoTherapy 66(3): 626-634, 2011

Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrobial Agents and ChemoTherapy 45(3): 981-985, 2001

Clinical efficacy and safety of itraconazole injection/oral solution sequential therapy for treatment of invasive fungal infection in intensive care unit. Zhonghua Nei Ke Za Zhi 47(12): 1012-1016, 2009

Hepatic safety of itraconazole intravenous solution in treatment of invasive fungal infection. Zhonghua Yi Xue Za Zhi 86(29): 2028-2032, 2006

The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea. Annals of Hematology 93(1): 33-42, 2014

Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. Journal of Clinical Pharmacology 41(12): 1319-1328, 2002

Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. Clinica Chimica Acta; International Journal of Clinical Chemistry 415: 128-132, 2013

Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in china. Japanese Journal of Infectious Diseases 59(6): 370-376, 2006

Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients. Brazilian Journal of Infectious Diseases 5(2): 60-66, 2001

The clinical efficacy and cardiac safety of itraconazole injection in treatment of acute pulmonary invasive fungal infection in chronic pulmonary diseases in the elderly. Zhonghua Nei Ke Za Zhi 49(3): 230-233, 2010

Efficacy of intravenous itraconazole against invasive pulmonary aspergillosis in neutropenic mice. Journal of Infection and ChemoTherapy 12(6): 355-362, 2007